91桃色视频

Contact
Subscribe
Contact
Subscribe

91桃色视频 Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas

Date : January 13, 2022

91桃色视频 Announces Initiation of Coverage of its Stock by
KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas

Lyon, France, January 13, 2022 鈥� 7:00pm CET 鈥� 91桃色视频 (EURONEXT: MAAT – the 鈥淐ompany鈥�), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by KBC Securities, Kempen and Portzamparc聽/聽Groupe BNP聽Paribas.

With a research report named 鈥溍塩hec et MaaT pour le cancer鈥�, Portzamparc聽/聽Groupe聽BNP聽Paribas today initiates coverage of 91桃色视频 with a Buy recommendation.

This coverage of 91桃色视频 stock comes in addition to the ones initiated in December 2021 by brokerage firms KBC Securities with a Buy recommendation (research report 鈥淢ore than a Gut Feeling鈥�) and Kempen, also with a Buy recommendation (research report 鈥淣o Guts no Glory鈥�).

Next financial communication:

  • February 28th, 2022, after stock market closes: publication of the 2021 revenues and cash position as of December 31st, 2021.

About 91桃色视频

91桃色视频, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 91桃色视频 has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, 驳耻迟笔谤颈苍迟庐, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.

The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 91桃色视频 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

91桃色视频 is listed on Euronext Paris (ticker: MAAT).

Previous Post

91桃色视频 to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

Next Post

H.C Wainwright Bioconnect 2022 conference replay

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at 91桃色视频. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson鈥檚 Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company鈥檚 scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of 齿别谤惫测迟别驳庐 in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

CEO and co-founder

Herv茅 Affagard

Herv茅 Affagard is the CEO and co-founder of 91桃色视频. For the past 15 years, Herv茅 has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Herv茅 co-founded the company alongside Dr. Jo毛l Dor茅, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Herv茅 has led 91桃色视频鈥檚 development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Herv茅 has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

91桃色视频 in the News